Profile data is unavailable for this security.
About the company
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.
- Revenue in USD (TTM)308.13m
- Net income in USD-29.34m
- Incorporated2010
- Employees246.00
- LocationCoherus BioSciences IncC/O DENNIS M. LANFEAR201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 649-3530
- Fax+1 (302) 655-5049
- Websitehttps://www.coherus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | 0.00 | -129.85m | 112.25m | 128.00 | -- | 0.4718 | -- | -- | -1.80 | -1.80 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -51.44 | -47.21 | -55.69 | -51.07 | -- | -- | -- | -- | -- | -- | 0.0028 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Nuvectis Pharma Inc | 0.00 | -21.10m | 112.48m | 13.00 | -- | 9.02 | -- | -- | -1.29 | -1.29 | 0.00 | 0.6682 | 0.00 | -- | -- | 0.00 | -97.61 | -- | -128.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Fractyl Health Inc | 119.00k | -65.88m | 114.55m | 102.00 | -- | 1.62 | -- | 962.57 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -30.58m | 116.96m | 140.00 | -- | 39.09 | -- | -- | -1.18 | -1.18 | 0.00 | 0.056 | 0.00 | -- | -- | 0.00 | -95.14 | -- | -154.95 | -- | -- | -- | -- | -- | -- | -21.58 | 0.8416 | -- | -- | -- | -11.06 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -42.29m | 117.41m | 11.00 | -- | 1.49 | -- | -- | -3.91 | -3.91 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -94.50 | -232.67 | -129.40 | -- | -- | -- | -- | -- | -- | -323.10 | 0.0626 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Verastem Inc | 10.00m | -89.49m | 117.51m | 73.00 | -- | 4.16 | -- | 11.75 | -3.34 | -3.34 | 0.3726 | 1.49 | 0.0672 | -- | 2.00 | 136,986.30 | -60.16 | -62.70 | -72.65 | -75.18 | -- | -- | -894.91 | -406.17 | -- | -- | 0.5052 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Seres Therapeutics Inc | 374.00k | -162.11m | 117.53m | 233.00 | -- | -- | -- | 314.26 | -1.18 | -1.18 | 0.0027 | -0.5742 | 0.001 | -- | 0.0286 | 1,605.15 | -44.53 | -41.51 | -59.82 | -54.13 | -- | -- | -43,343.58 | -170.14 | 0.889 | -17.64 | 6.65 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| INmune Bio Inc | 85.00k | -37.74m | 117.74m | 11.00 | -- | 2.82 | -- | 1,385.13 | -2.06 | -2.06 | 0.0046 | 1.88 | 0.0014 | -- | 0.0311 | 7,727.27 | -61.78 | -37.82 | -80.24 | -41.86 | -- | -- | -44,402.35 | -14,901.03 | -- | -23.01 | 0.1184 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -137.29m | 117.83m | 143.00 | -- | 0.5012 | -- | -- | -2.53 | -2.53 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -50.25 | -37.03 | -53.87 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Quantum-Si Inc | 1.70m | -89.35m | 119.18m | 159.00 | -- | 0.5108 | -- | 70.03 | -0.6302 | -0.6302 | 0.012 | 1.64 | 0.0057 | 0.2321 | 3.68 | 10,704.40 | -29.89 | -- | -30.99 | -- | 53.41 | -- | -5,249.65 | -- | 20.13 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
| Coherus Biosciences Inc | 308.13m | -29.34m | 119.82m | 246.00 | -- | -- | -- | 0.3889 | -0.4014 | -0.4014 | 2.74 | -0.7301 | 0.5385 | 2.86 | 1.95 | 1,006,974.00 | -5.13 | -21.43 | -11.46 | -29.32 | 41.51 | 79.01 | -9.52 | -36.56 | 1.07 | -4.02 | 1.47 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Fennec Pharmaceuticals Inc | 48.89m | 2.74m | 123.39m | 36.00 | 115.94 | -- | 45.12 | 2.52 | 0.0389 | 0.0389 | 1.75 | -0.0497 | 1.18 | 1.21 | 6.63 | -- | 6.62 | -73.43 | 7.70 | -84.32 | 95.55 | -- | 5.59 | -383.28 | 7.75 | 1.87 | 1.05 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Outlook Therapeutics Inc | 0.00 | -94.05m | 123.48m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Century Therapeutics Inc | 2.04m | -131.39m | 123.69m | 152.00 | -- | 0.5558 | -- | 60.57 | -2.04 | -2.04 | 0.031 | 2.63 | 0.0049 | -- | -- | 13,434.21 | -31.52 | -- | -33.04 | -- | -- | -- | -6,434.23 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| Cardiff Oncology Inc | 665.00k | -40.88m | 127.55m | 31.00 | -- | 2.39 | -- | 191.80 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Sagimet Biosciences Inc | 2.00m | -29.25m | 127.65m | 10.00 | -- | 0.6904 | -- | 63.83 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
Data as of Oct 09 2024. Currency figures normalised to Coherus BioSciences Inc's reporting currency: US Dollar USD
42.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 31 Mar 2024 | 10.40m | 9.07% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.90m | 8.63% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 8.80m | 7.67% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 22 Jul 2024 | 5.54m | 4.83% |
| Citadel Advisors LLCas of 31 Mar 2024 | 2.63m | 2.29% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.63m | 2.29% |
| Geode Capital Management LLCas of 30 Jun 2024 | 2.38m | 2.08% |
| Barclays Bank Plc (Private Banking)as of 31 Mar 2024 | 2.05m | 1.79% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.00m | 1.74% |
| C WorldWide Asset Management Fondsm�glerselskab A/Sas of 30 Jun 2024 | 1.93m | 1.68% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
